Clinical pharmacology consultation: a better answer to safety issues of drug therapy during pregnancy?
- First Online:
- 122 Downloads
Drug safety classifications give a very basic estimation of risk and should only be used as general guideline when assessing risk of pregnancy-related drug exposure or planning treatment. We conducted a study to assess the strength of association between both the clinical pharmacologists’ risk assessment and the FDA risk categorization, and adverse pregnancy outcomes.
We retrospectively reviewed records of 1,076 patients consecutively referred to the clinical pharmacology outpatient clinic for pregnancy-related drug exposure (2000–2008). Clinical pharmacologists’ risk assessments were reviewed in relation to FDA drug categorization and available pregnancy outcomes.
Overall, clinical pharmacologists’ risk estimation was in agreement with the FDA risk categorization system in only 28% of consulted women, and in only 9% of women with high-risk exposure (FDA DX). Clinical pharmacologists’ risk assessment confirming high-risk drug exposure had a better positive predictive value for adverse pregnancy outcomes than the FDA DX categorization (25% vs 14% respectively), while the negative predictive values were similar (92% vs 94% respectively). Clinical pharmacologists’ risk assessment was a better predictor of adverse pregnancy outcomes compared with FDA risk categorization (OR 2.11 [95%CI 1.5-3.1; p < 0.001] vs OR 1.52 [95%CI 1.1-2.1; p = 0.014] respectively).
Additional evaluation beyond the FDA drug classification is essential for safer and more rational drug use in pregnancy. Clinical pharmacologists who have undergone rigorous medical training are ideally placed to consult on administration of medicines in pregnant women, thus making the prescribing of treatments in that patient category substantially safer and more rational.
Key wordsPregnancy-related drug exposure FDA Drug safety classifications Clinical pharmacology Risk assessment Drug safety
- 2.Koren G (1994) Maternal-fetal toxicology: a clinician’s guide. Dekker, New YorkGoogle Scholar
- 4.Haramburu F, Miremont G, Moride Y, Gomez MP, Douchet P, Douet C (1995) Drug prescription during pregnancy: a cohort study. Pharmacoepidemiol Drug Saf 4:74Google Scholar
- 6.Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, Fraser W, Olatunbosun O, Wen SW (2008) Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf 17(3):270–277. doi:10.1002/pds.1538 CrossRefPubMedGoogle Scholar
- 12.Bencarić L (2009) Registar Lijekova u Hrvatskoj. Udruga poslodavaca u zdravstvu, ZagrebGoogle Scholar
- 13.Vrhovac B et al (2007) Farmakoterapijski priručnik. Medicinska naklada, ZagrebGoogle Scholar
- 14.http://www.entis-org.com/en/aboutus.php. Accessed 2 June 2010
- 15.http://www.otispregnancy.org/goals-and-mission-s13030. Accessed 2 June 2010
- 16.ADEC: Australian Drug Evaluation Committee (1996) Medicines in Pregnancy—an Australian categorisation of risk of drug use in pregnancy. Australian Government Publishing Service, CanberraGoogle Scholar
- 18.British Medical Association and Royal Pharmaceutical Society of Great Britain (2009) British National Formulary. BMJ Group and RPS Publishing, LondonGoogle Scholar
- 19.American Society of Health-System Pharmacists (2008) AHFS Drug Information. American Society of Health-System Pharmacists, BethesdaGoogle Scholar
- 20.Briggs DD (2008) Drugs in pregnancy and lactation. Lippincot Williams Wilkins, PhiladelphiaGoogle Scholar
- 21.Micromedex® Healthcare Series Vol. 144, expires 6/2010Google Scholar
- 22.www.ncbi.nlm.nih.gov/pubmed/. Accessed 2 June 2010
- 27.Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, McPhillips H, Roblin D, Smith DH, Yood MU, Platt R, Gurwitz JH (2006) Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 15(8):546–554. doi:10.1002/pds.1235 CrossRefPubMedGoogle Scholar
- 28.http://www.dzs.hr/Hrv_Eng/menandwomen/men_and_women_2009.pdf. Accessed 2 June 2010
- 29.Adams P, Hendershot G, Marano M (1999) Current estimates from the National Health Interview Survey. Vital Health Stat 10:83–84Google Scholar
- 30.Kovacić L, Gazdek D, Samardzić S (2007) Croatian health survey: cigarette smoking. Acta Med Croat 61(3):281–285Google Scholar
- 31.http://www.hzjz.hr/publikacije/porodi2008.pdf. Accessed 2 June 2010
- 32.Briggs GG, Freeman RK, Yaffe JS (2008) Drugs in pregnancy and lactation. Lippincott Williams & Willkins, PhiladelphiaGoogle Scholar
- 36.http://www.hzjz.hr/publikacije/prekidi_2008.pdf. Accessed 2 June 2010
- 41.Engeland A, Bramness JG, Dalveit AK, Ronning M, Skurtveit S, Furu K (2008) Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 65(5):653–660. doi:10.1111/j.1365-2125.2008.03102.x CrossRefPubMedGoogle Scholar
- 43.Samrén EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, Mannagetta GB, Deichl AW, Gaily E, Granström ML, Meinardi H, Grobbee DE, Hofman A, Janz D, Lindhout D (1997) Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38:981–990CrossRefPubMedGoogle Scholar